Maxcyte (MXCT) Revenue (2020 - 2026)

Maxcyte (MXCT) has 7 years of Revenue data on file, last reported at $9.7 million in Q1 2026.

• Revenue for Q1 2026 came in at $9.7 million, up 68.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.5 million (down 36.38% YoY), and the FY2025 annual result was $21.0 million, down 45.75% from the prior year.
• Revenue climbed to $9.7 million in Q1 2026 per MXCT's latest filing, from -$4.8 million in the prior quarter.
• Over five years, Revenue peaked at $11.6 million in Q1 2022 and troughed at -$4.8 million in Q4 2025.
• A 5-year average of $5.8 million and a median of $5.8 million in 2025 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2025: Revenue soared 253.92% in 2023, then sank 154.86% in 2025.
• A 5-year view of Revenue shows it stood at -$3.1 million in 2022, then soared by 253.92% to $4.8 million in 2023, then surged by 82.78% to $8.7 million in 2024, then slumped by 154.86% to -$4.8 million in 2025, then jumped by 302.37% to $9.7 million in 2026.
• Business Quant data shows MXCT's Revenue at $9.7 million in Q1 2026, -$4.8 million in Q4 2025, and $6.8 million in Q3 2025.